OFEV Slows Progression of Fibrosis, Lung Imaging in Phase 3b Trial Shows
Pulmonary fibrosis treatment OFEV (nintedanib) slows the progression of lung scarring, according to high-resolution scans used in a Phase 3b clinical trial. Computed tomography imaging demonstrated for the first time that six months of Ofev could reduce the progression of patients’ lung fibrosis lesions, compared with a placebo. Two…